184 results
Page 2 of 10
8-K
EX-99.1
nzdefo 99
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
8-K
c8kuodf2
4 Apr 23
Other Events
8:30am
8-K
EX-99.1
2c8mkhjhtmmhpmsuvmme
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
8-K
EX-99.1
zqk2sdwnu0c2rhos
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am
8-K
EX-99.1
dvb0ppiv81xbhnl97u61
11 May 22
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones
8:30am
8-K
EX-99.1
2wwcra45unmjg4a3qs
23 Mar 22
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
4:05pm
8-K
EX-99.1
3xyf1a
22 Dec 21
Regulation FD Disclosure
8:30am
8-K
EX-99.1
q5kvvkwmj6qx53
15 Nov 21
Cocrystal Pharma Reports Third Quarter Financial Results and Provides an Update on Development
8:00am
8-K
EX-1.1
jtmcrjeyf8cf2pm 20
5 May 21
Entry into a Material Definitive Agreement
5:02pm
424B5
hyt6m er2a
5 May 21
Prospectus supplement for primary offering
4:01pm
8-K
EX-99.1
lt5romn2gt7uqzf
5 May 21
Cocrystal Pharma Announces $40 Million Bought Deal Offering of Common Stock
7:52am
8-K
02c5nqs
19 Feb 21
Amendments to Articles of Incorporation or Bylaws
8:30am